Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | PRKCG | P05129 | 2/20 | 0.41 |
| ▸ | PRKCB | P05771 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | PRKCH | P24723 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 5/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820179 | 1.00 | PRKD3 (0.41) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL13225891 | 1.00 | PRKD3 (0.41) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL51157 | 0.90 | — | — | |
| SCHEMBL13166788 | 0.89 | CYP2C9 (0.44) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL19067466 | 0.89 | CYP2C9 (0.44) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL19546092 | 0.89 | PRKD3 (0.36) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL19749216 | 0.87 | LPAR1 (0.42) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL12355616 | 0.87 | PRKD3 (0.39) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14730146 | 0.87 | PRKD3 (0.35) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL26709585 | 0.87 | LPAR1 (0.42) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773277-B2 | Use of an ultraviolet radiation absorbing polymer composition (UVRAP) as an UV absorbing agent in a coating for non-living and non-keratinous materials | BASF SE | 2023-10-03 | — | — | US | disclosed |
| EP-2906246-B1 | VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| US-20170281481-A1 | Topical composition comprising plant extracts | LINNEA SA (CH) | 2017-10-05 | — | — | US | disclosed |
| US-8741283-B2 | Adenosine deaminase anticancer therapy | SIGMA-TAU RARE DISEASES, S.A. (PT) | 2014-06-03 | — | — | US | disclosed |
| US-8268318-B2 | Polyalkylene oxides having hindered ester-based biodegradable linkers | ENZON PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8110559-B2 | Hindered ester-based biodegradable linkers for oligonucleotide delivery | ENZON PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8071741-B2 | Stable recombinant adenosine deaminase | DEFIANTE FARMACEUTICA, S.A. (PT) | 2011-12-06 | — | — | US | disclosed |
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | ENZON PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100234444-A1 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | ENZON PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090016985-A1 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY | ENZON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080159964-A1 | USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE | ENZON PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279408-A1 | POLYMERIC SHORT INTERFERING RNA CONJUGATES | SNRPE, RNASE1, PHAX | PRKD3 2283/4885PRKCG 3375/4885PRKCB 3488/4885 |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | RNASE1, ADA, DCTD | PRKD3 2630/4885PRKCG 2192/4885PRKCB 1875/4885 |
| US-20080159964-A1 | USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE | ADA, AMPD2, AMPD1 | PRKD3 1038/4885PRKCG 623/4885PRKCB 838/4885 |
| US-20090017004-A1 | POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID | AADAC, ACSS2, ANXA6 | PRKD3 4642/4885PRKCG 4213/4885PRKCB 4440/4885 |
| US-20090202573-A1 | POLYMERIC CONJUGATES CONTAINING POSITIVELY-CHARGED MOIETIES | PIGO, PHOSPHO1, PAICS | PRKD3 3204/4885PRKCG 1971/4885PRKCB 3225/4885 |
| US-20090016985-A1 | POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY | ABCB1, PAICS, ABCG2 | PRKD3 4671/4885PRKCG 4829/4885PRKCB 4834/4885 |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | CES2, PLOD3, FASN | PRKD3 4095/4885PRKCG 3061/4885PRKCB 2523/4885 |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1B, IL1R1 | PRKD3 2914/4885PRKCG 2097/4885PRKCB 1744/4885 |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ADA, CDA, DCTD | PRKD3 752/4885PRKCG 1493/4885PRKCB 1540/4885 |
| US-20170281481-A1 | Topical composition comprising plant extracts | CHMP4B, EXOSC9, EXOSC5 | PRKD3 2648/4885PRKCG 2080/4885PRKCB 2509/4885 |
| US-20100234444-A1 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | VEGFA, DCLRE1B, MSN | PRKD3 4454/4885PRKCG 4060/4885PRKCB 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.